Firebrick Pharma (ASX:FRE) ROCE % : -89.64% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Firebrick Pharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Firebrick Pharma's annualized ROCE % for the quarter that ended in Dec. 2023 was -89.64%.

Firebrick Pharma ROCE % Historical Data

The historical data trend for Firebrick Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firebrick Pharma ROCE % Chart

Firebrick Pharma Annual Data

Trend

Jun21

Jun22

Jun23

ROCE %

-38.24

-127.64

Firebrick Pharma Semi-Annual Data
	Jun22	Dec22	Jun23	Dec23
ROCE %	-	-93.96	-195.40	-89.64

Firebrick Pharma ROCE % Calculation

Firebrick Pharma's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-6.864	/	( ( (8.729 - 0.45)	+	(2.982 - 0.506) )	/ 2 )
	=	-6.864	/	( (8.279	+	2.476)	/ 2 )
	=	-6.864	/	5.3775
	=	-127.64 %

Firebrick Pharma's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-1.822	/	( ( (2.982 - 0.506)	+	(1.945 - 0.356) )	/ 2 )
	=	-1.822	/	( ( 2.476	+	1.589 )	/ 2 )
	=	-1.822	/	2.0325
	=	-89.64 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Firebrick Pharma (ASX:FRE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Firebrick Pharma ROCE % Related Terms

Thank you for viewing the detailed overview of Firebrick Pharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Firebrick Pharma (ASX:FRE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

440 Collins Street, Level 10, Melbourne, VIC, AUS, 3000

Website

https://www.firebrickpharma.com

Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of Nasodine, a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold.

Firebrick Pharma (ASX:FRE) Headlines

No Headlines